Related Experiment Video
Updated: Apr 28, 2026
08:49
Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems
Published on: August 2, 2024
1.4K
Inotropes do not increase mortality in advanced heart failure
1University of South Florida, Tampa, FL, USA.
International Journal of General Medicine
|June 6, 2014
Summary
The evidence linking inotropes like dobutamine and milrinone to increased mortality in heart failure patients with low output is insufficient. Further research is needed to clarify their role in managing advanced heart failure.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Inotrope use in heart failure management is controversial, with registry data suggesting high mortality.
- Randomized trials are scarce due to ethical considerations and may not reflect current practice.
Purpose of the Study:
- To review current indications for inotropes (dobutamine, milrinone) in heart failure.
- To examine the evidence linking inotropes to increased mortality in low output heart failure.
Main Methods:
- Literature review of inotropic agents, focusing on dobutamine and milrinone.
- Analysis of current clinical practice patterns and inotrope dependency.
Main Results:
- Existing randomized control trials have mixed results and limitations in applicability to current practice.
- Retrospective data often shows high mortality in patients requiring inotropes, but this may reflect advanced disease.
Conclusions:
- The current evidence is insufficient to definitively link inotropes to increased mortality in low output heart failure.
- Further investigation is warranted to clarify the risk-benefit profile of inotropes in specific heart failure populations.
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
1.9K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.9K
01:30Heart Failure V: Medical Management
622
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
622
01:22Heart Failure Drugs: β-Blockers
2.6K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.6K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.7K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.7K
01:22Heart Failure Drugs: Diuretics
1.5K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.5K
01:22Heart Failure VI: Adjunct Therapies
631
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
631